Gilead Sciences revealed it has entered into a definitive agreement to acquire an oral interleukin (IL)-23R inhibitor program ...
US pharma major AbbVie yesterday announced positive top-line results from the Phase III INTREPID study evaluating the safety ...
Advanced Clinical which is providing full-service clinical development, functional service provider (FSP) solutions and ...
Senior vice president tells The Pharma Letter how the US biotech major challenged the big pharma playbook, pairing a central ...
Boston, USA-based AI Proteins, a biotech that uses computational de novo protein design to create therapeutic miniproteins, ...
Georgiamune, the US clinical-stage immunology biotech, has granted Stemline Therapeutics, the oncology subsidiary of Italy’s ...
Germany's BioNTech has teamed up with Gilead Sciences to test its experimental cancer therapy in combination with the US ...
Privately-held German pharma company Boehringer Ingelheim and Microsoft have announced a strategic collaboration to ...
Japan’s Shionogi and UK-based F2G Ltd today announced results from the global Phase III OASIS study, in a late-breaking oral ...
INmune Bio Inc, a late-stage biotechnology company focused on inflammation and immunology, today announced that it has ...
Pharma major Roche reported third-quarter 2026 group sales of 16.13 billion Swiss francs ($19.61 billion), up 7% at constant ...
South Korea’s Samsung Bioepis today released its fourth quarter 2026 Market report, marking the fifteenth edition of the review on developments in the USA.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results